Top Institutions in Medical Oncology
Based on known institutional expertise and research leadership, top cancer centers with strong thoracic oncology programs and immunotherapy clinical trials leadership are prioritized. These institutions have contributed significantly to lung cancer immunotherapy research, multidisciplinary treatment approaches, and real-world evidence generation.
-
#1
Memorial Sloan Kettering Cancer Center
New York, NY
MSKCC is a global leader in lung cancer research and immunotherapy clinical trials, with extensive expertise in multidisciplinary management of oligometastatic NSCLC and real-world evidence studies.
Key Differentiators
- Medical Oncology
- Thoracic Oncology
- Immunotherapy
-
#2
Dana-Farber Cancer Institute
Boston, MA
Dana-Farber has a leading thoracic oncology program with significant contributions to immunotherapy research and clinical trials in NSCLC, including studies on treatment sequencing and oligometastatic disease.
Key Differentiators
- Medical Oncology
- Thoracic Oncology
- Immunotherapy
-
#3
MD Anderson Cancer Center
Houston, TX
MD Anderson is renowned for its comprehensive lung cancer program, combining cutting-edge immunotherapy research with expertise in local radical treatments such as radiation therapy for oligometastatic NSCLC.
Key Differentiators
- Medical Oncology
- Thoracic Oncology
- Radiation Oncology
-
#4
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Johns Hopkins has a robust thoracic oncology program with active research in immunotherapy sequencing and oligometastatic NSCLC management, contributing to clinical guidelines and real-world evidence.
Key Differentiators
- Medical Oncology
- Thoracic Oncology
- Immunotherapy
-
#5
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
UCSF is recognized for its innovative lung cancer research, including immunotherapy and local treatment strategies in oligometastatic NSCLC, with strong multidisciplinary collaboration and translational research.
Key Differentiators
- Medical Oncology
- Thoracic Oncology
- Immunotherapy
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
